BioWisdom Launches OmniViz Academic Program

BioWisdom has launched an exclusive program that gives access to its OmniViz visualization and analysis software to academics and not-for-profit organisations at a heavily discounted price of $999.

"In the last few years BioWisdom has created a world class capability for providing healthcare intelligence to the pharmaceutical industry," said Gordon Baxter, CEO. "The core of this strategy has been and remains the rapidly emerging field of ontology as applied to life sciences research and development, delivered through BioWisdom's proprietary platform Sofia. BioWisdom is now preparing to enter the next stage of its growth, bringing the value of this leadership in life sciences ontology to the desktops of individual scientists globally through both of the recently acquired technologies, SRS and OmniViz."

"OmniViz can analyze extremely large collections of experimental, numerical, categorical, genomic or chemical data, and analyze internal and external literature, patents and competitive intelligence information," added Dr Michael R Stapleton, BioWisdom's Chief Business Officer. "It provides a unique ability to discover, prioritize and test decisions and hypotheses. As part of BioWisdom's long standing collaboration and commitment to the academic and not-for-profit organizations and building on the similar program in place for BioWisdom's bioinformatics platform SRS, we are pleased to be able to make the full power of OmniViz available to the global academic community with the announcement of this exciting program."

For more information about OmniViz, including purchasing an academic licence, please visit www.biowisdom.com/content/omniviz